A Phase 1, Open-label, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of TAK-385 Alone in Hormone Treatment- naïve Japanese Patients With Non-metastatic Prostate Cancer
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 43
- 主要终点
- Part A: Number of Participants With Dose-limiting Toxicities (DLTs)
研究概览
简要总结
The purpose of this study is to evaluate the tolerability and safety of TAK-385 in hormone treatment-naïve participants with non-metastatic prostate cancer.
详细描述
The objective of this study is to evaluate the tolerability and safety of TAK-385 in hormone treatment-naive participants with non-metastatic prostate cancer. This study consists of two parts: Part A, multiple dose-rising (MRD) phase and Part B, an expansion phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Participants judged by the investigator to have the capacity to understand the study and follow the study rules.
- •Participants whose written consent (signature or printed name and personal seal on informed consent form) can be obtained before any study procedures are performed.
- •Japanese male participants 20 or more years of age at the time of informed consent.
- •Participants who, if they have a female partner who could become pregnant, agree to practice appropriate means of contraception from the time of informed consent throughout the entire study treatment period and for 4 months after the last dose of study drug.
- •Participants in stable medical condition, including the absence of acute exacerbations of chronic illnesses, serious infections, or major surgery within 4 weeks (28 days) prior to study treatment initiation.
- •Participants with histologically or cytologically confirmed prostate cancer.
- •Participants whose clinical diagnosis is T1-4 N0 M0, or Tx N0 M0 for participants who have undergone radical prostatectomy.
- •Participants who are considered eligible for hormone therapy for prostate cancer.
- •Participants who have not received hormone therapy (example, gonadotropin-releasing hormone [GnRH] agonist, GnRH antagonist, steroidal antiandrogen, non-steroidal androgen) for prostate cancer.
- •Participants who have not undergone surgical castration.
- •Participants with serum testosterone at screening greater than (>) 150 nanogram per deciliter (ng/dL).
- •Participants meeting either of the following criteria for prostate-specific antigen (PSA) at screening. Untreated prostate cancer: PSA at screening > 4.0 nanogram per milliliter (ng/mL) Treated* prostate cancer: PSA at screening > 0.2 ng/mL.
- •Participants who have undergone prostatectomy or either or both of high intensity focused ultrasound therapy or radiotherapy (excluding 125I-brachytherapy) prior to the start of this study.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status [17] of 0 or
- •Body mass index (BMI) at screening greater than or equal to (>=) 18.0 kilogram per square meter (kg/m^2).
排除标准
- •Participants exhibiting symptoms judged related to prostate cancer by the investigator (example, bone pain, pelvic pain, ureteral obstruction) who urgently require hormone therapy such as GnRH agonist, GnRH antagonist, or CAB/MAB therapy, chemotherapy, or radiotherapy.
- •Participants who have received 5-alpha reductase inhibitors (except for participants who have been treated for male-pattern alopecias).
- •Participants who have received chemotherapy for prostate cancer (including estramustine).
- •Participants who have received 125I-brachytherapy.
- •Participants who received radiotherapy (except for 125I-brachytherapy) within 16 weeks (112 days) before study treatment initiation.
- •Participants who underwent prostatectomy within 16 weeks (112 days before study treatment initiation.
- •Treatment with any investigational compound within the 4 weeks (28 days) prior to the first dose of study drug or ongoing participation in another experimental trial related to the treatment of prostate cancer.
- •Diagnosis or treatment for another systemic malignancy within 2 years before study treatment initiation, or who had received a diagnosis of another malignancy before that and have evidence of residual disease. Participants with non-melanoma skin cancer or carcinoma in situ who have undergone complete resection will not be excluded from the study.
- •Participants taking drugs with moderate to strong cytochrome P450 3A4 (CYP3A4) inhibitory or inducing effects, or any medications, supplements, or food products with P-glycoprotein (P-gp) inhibitory effects, in the 2 weeks (14 days) prior to study treatment initiation.
- •Participants who have received TAK-385 in a past clinical study.
- •Participants for whom it would be difficult to collect blood from a peripheral vein.
- •Participants with uncontrolled and clinically significant nervous, circulatory, pulmonary, hepatic, renal, metabolic, gastrointestinal, urogenital, or endocrine disorders, or other abnormalities (except for the targeted disease) that could affect study participation or the study results. Also, participants meeting any of criteria a through c below.
- •A. Participants with uncontrolled diabetes (Hemoglobin A1c [HbA1C] > 8 percent [%] at screening). However, participants whose HbA1c is brought under control with diabetes medications may be rescreened.
- •B. Participants with uncontrolled hypertension (systolic blood pressure > 150 millimeter of mercury (mmHg) and diastolic blood pressure > 90 mmHg at 2 separate measurements taken no more than 60 minutes apart at screening). Participants whose blood pressure is brought under control by antihypertensive medication may be rescreened.
- •C. Participants with myocardial infarction, unstable symptomatic ischemic heart disease, arrhythmias of common terminology criteria for adverse events (CTCAE) Grade > 2, thromboembolism (deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or other heart diseases (example, pericardial effusion, restrictive cardiomyopathy). However, chronic stable atrial fibrillation controlled by stable anticoagulant therapy will be allowed.
- •Participants with bilateral hydronephrosis or bladder neck outlet obstruction.
- •Known hypersensitivity to TAK-385, TAK-385 excipients, or gonadotropin-releasing hormone (GnRH) antagonists.
- •Participants with a past history of gastrointestinal tract treatments (including gastrectomy) or gastrointestinal disease that could affect the drug absorption or tolerability (malabsorption, esophageal reflux, peptic ulcer, erosive esophagitis).
- •Participants positive for hepatitis B surface antigens (HBsAg), hepatitis C antibodies (HCV), human immunodeficiency virus (HIV) antibodies, or serologic test for syphilis, or with life-threatening disease other than cancer, at screening.
- •Clinically relevant electrocardiogram (ECG) abnormalities, or the following ECG abnormalities, at screening.
- •Q-wave infarction, unless identified 6 or more months prior to TAK-385 treatment initiation.
- •QTcF interval > 450 millisecond (msec) (when calculating the QTc interval, Fridericia's equation [QT/RR0.33] will be used).
- •Participants with congenital QT prolongation.
- •Current use of Class 1A or Class 3 antiarrhythmic medications.
- •New York Heart Association Class III or IV heart failure.
- •Participants with clinical laboratory abnormalities suggesting clinically relevant underlying disease, or with any of the following abnormal results, at screening.
- •Serum creatinine >= 2.0 mg/dL.
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >= 1.5*upper limit of normal (ULN) for the study site.
- •Total bilirubin >= 2*ULN for the study site.
- •Neutrophil count less than (<) 1,500 per cubic millimeter (/mm^3), platelet count < 100,000 per microliter (/mcL), hemoglobin < 10.0 g/dL.
- •Results of heart-related tests (creatine kinase MB [CK-MB] and cardiac troponin T) exceeding the study sites reference value.
- •Participants found to have clinical problems on the basis of examination findings, ECG findings, or chest X-ray findings at screening.
- •Participants considered unlikely by investigators to be able to follow the study protocol or considered ineligible for the study by investigators for other reasons.
研究组 & 干预措施
Part A Cohort 1: TAK-385 320 mg + TAK-385 80 mg
TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 80 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
干预措施: TAK-385 (Drug)
Part A Cohort 2: TAK-385 320 mg + TAK-385 120 mg
TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
干预措施: TAK-385 (Drug)
Part A Cohort 3: TAK-385 320 mg + TAK-385 160 mg
TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 160 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
干预措施: TAK-385 (Drug)
Part A Cohort 4: TAK-385 360 mg + TAK-385 120 mg
TAK-385 360 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
干预措施: TAK-385 (Drug)
Part B Cohort 1: TAK-385 320 mg + TAK-385 80 mg
TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 80 mg maintenance dose, tablet, orally, once daily through Days 2 to 672.
干预措施: TAK-385 (Drug)
Part B Cohort 2: TAK-385 320 mg + TAK-385 120 mg
TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 672.
干预措施: TAK-385 (Drug)
结局指标
主要结局
Part A: Number of Participants With Dose-limiting Toxicities (DLTs)
时间窗: From treatment initiation until Day 28
DLTs were defined as treatment-related adverse events (AEs) that occurred within the first 28 days of treatment as per common terminology criteria for adverse events (CTCAE) version 4.03: any grade 3 or higher toxicity; QT/Fridericia corrected QT (QTcF) greater than (\>) 500 millisecond (msec) after treatment initiation; QT/QTcF interval prolongation \>60 msec postdose.
Part A: Number of Participants With Markedly Abnormal Values of Electrocardiogram (ECG) Parameters
时间窗: From treatment initiation until 40 days after last dose of study drug (Day 68)
Part B: Number of Participants With Markedly Abnormal Values of Vital Signs Parameters
时间窗: From treatment initiation until 40 days after last dose of study drug (Day 712)
Here "BP" is blood pressure.
Part A: Number of Participants Reporting One or More Treatment-emergent Adverse Event (TEAE)
时间窗: From treatment initiation until 40 days after last dose of study drug (Day 68)
Part B: Number of Participants Reporting One or More TEAE
时间窗: From treatment initiation until 40 days after last dose of study drug (Day 712)
Part A: Number of Participants With Markedly Abnormal Values of Vital Signs Parameters
时间窗: From treatment initiation until 40 days after last dose of study drug (Day 68)
Part B: Number of Participants With Markedly Abnormal Values of ECG Parameters
时间窗: From treatment initiation until 40 days after last dose of study drug (Day 712)
Part A: Number of Participants With Grade 2 or Higher Laboratory Test Abnormalities
时间窗: From treatment initiation until 40 days after last dose of study drug (Day 68)
Laboratory test abnormalities were graded using the CTCAE. The grades were: Grade 2- (moderate) minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activity of daily living (ADL); Grade 3- (severe) medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limited self-care ADL. Data has been presented for any Grade 2 or higher event in the laboratory test abnormalities.
Part B: Number of Participants With Grade 2 or Higher Laboratory Test Abnormalities
时间窗: From treatment initiation until 40 days after last dose of study drug (Day 712)
Laboratory test abnormalities were graded using the CTCAE. The grades were: Grade 2- (moderate) minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL; Grade 3- (severe) medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limited self-care ADL. Data has been presented for any Grade 2 or higher event in the laboratory test abnormalities. Here aspartate aminotransferase (AST) (glutamic-oxaloacetic transaminase \[GOT\]) High, creatine kinase (CK) (creatine phosphokinase \[CPK\]) High, prothrombin time (PT)-international normalized ratio (INR) High.
次要结局
- Part A: Serum Testosterone Concentrations for TAK-385(Up to Day 35)
- Part B: Percent Change From Baseline in PSA Levels on Week 13 Day 1 Last Observation Carried Forward (LOCF)(Baseline, and Week 13 Day 1 (LOCF; up to Week 13 Day 1))
- Part B: Serum Testosterone Concentrations for TAK-385(Up to Week 97 Day 1)
- Part A: Cmax: Maximum Observed Plasma Concentration for Unchanged TAK-385 on Day 1, 14 and 28(Days 1, 14 and 28 pre-dose and at multiple time points (up to 12 hours for Days 1 and 14; up to 72 hours for Day 28) post-dose)
- Part A: AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to (Tau) Over the Dosing Interval for Unchanged TAK-385 on Day 1, 14 and 28(Days 1, 14 and 28 pre-dose and at multiple time points (up to 12 hours for Days 1 and 14; up to 72 hours for Day 28) post-dose)
- Part B: Plasma Concentration of Unchanged TAK-385(Up to Week 49 Day 1)